Vlad Bratucu*
Leiomyosarcoma (LMS), a malignant soft tissue tumor arising from smooth muscle cells, presents a significant therapeutic challenge due to its aggressive nature and limited treatment options. Conventional treatments such as surgery, chemotherapy, and radiation have shown limited efficacy, prompting the exploration of novel therapeutic strategies. Among these, targeted therapy has emerged as a promising approach, offering the potential to improve outcomes for patients with LMS. In this article, we delve into the current landscape of targeted therapy for LMS and explore the promising future directions in this field.
Comparte este artículo
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 